Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bausch & Lomb gets option to Mimetogen's Phase II dry eye syndrome candidate; option period has expired

Executive Summary

Eye health giant Bausch & Lomb Inc., which is in the process of being acquired by Valeant Pharmaceuticals International Inc. for $8.7bn, has received an option to license exclusive worldwide rights to the Phase II dry eye syndrome (DES) candidate MIMD3 from Mimetogen Pharmaceuticals Inc.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies